scholarly journals Comparison of Serum Albumin, Serum C-Reactive Protein, and Pulse Wave Velocity as Predictors of the 4-Year Mortality of Chronic Hemodialysis Patients

2011 ◽  
Vol 18 (12) ◽  
pp. 1071-1079 ◽  
Author(s):  
Nobuyuki Amemiya ◽  
Tetsuya Ogawa ◽  
Kuniaki Otsuka ◽  
Yoshitaka Ando ◽  
Kosaku Nitta
Hypertension ◽  
2009 ◽  
Vol 53 (2) ◽  
pp. 150-157 ◽  
Author(s):  
Wiebke Schumacher ◽  
John Cockcroft ◽  
Nicholas J. Timpson ◽  
Carmel M. McEniery ◽  
John Gallacher ◽  
...  

2020 ◽  
Vol 35 (Supplement_3) ◽  
Author(s):  
Nevi Pasko ◽  
Ariana Strakosha ◽  
Arieta Dedej ◽  
Loredana Kapidani ◽  
Fjona Nasto ◽  
...  

Abstract Background and Aims Among hemodialysis patients, peripheral arterial disease (PAD) represents an important health care burden and has been associated with high mortality. The ancle-brachial index (ABI), is a reliable and noninvasive method used to asses PAD. The aim of this study was to evaluate the prevalence of PAD in patients undergoing chronic hemodialysis and the association with inflammation and malnutrition using serum C-reactive protein (CRP) and serum albumin as biomarkers. Method The study was conducted at different hemodialysis centers in patients receiving hemodialysis three times a week. We excluded patients with atrial fibrillation or who had been recently hospitalized. The ABI has been used as a diagnostic tool for PAD and measured before a hemodialysis session. A value of ABI less than 0.9 was considered abnormal. To better estimate the impact of malnutrition and inflammation we used the serum albumin, blood lipids values and serum C-reactive protein values defined by calculating the mean of the last three measurements. Results A total of 261 ESRD patients on maintenance hemodialysis were enrolled in the study. Mean age was 56.0 (±12) years, 58% were males, and 17.6% were diabetics. Mean time on hemodialysis was 5.9 (±6.7) years, with 24% of patients on dialysis for less than 3 years. Among our patients we found that the prevalence of PAD was 23.4%, of whom 58.1% were men. We found that age, diabetes, duration of hemodialysis, low serum albumin levels and high serum triglyceride levels were risk factors for PAD in hemodialysis patients. The multivariate analysis of our study has shown that a lower level of albumin and higher level of CRP were significantly associated with an ABI less than 0.9 (odds ratio, 4.54; 95% confidence interval, P = 0.017) after adjusting for demographic, clinical, biochemical and medication data. We did not find significant differences in serum calcium, phosphate or PTH levels between patients with PAD and those without it. Conclusion In conclusion, the present study showed high prevalence of PAD in patients on hemodialysis. The prevalence was higher in diabetics. Low albumin levels and C-reactive levels were independent risk factors of PAD. We found that early diagnosis and treatment of PAD could help to improve the quality of life of hemodialysed patients and postpone arterial complications in this group of patients.


2019 ◽  
Vol 32 (5) ◽  
pp. 789-796 ◽  
Author(s):  
Lixia Sun ◽  
Chunhong Ning ◽  
Jiqiang Liu ◽  
Tao Yao ◽  
Li Zhang ◽  
...  

2011 ◽  
Vol 15 (3) ◽  
pp. 326-333 ◽  
Author(s):  
Serena TORRACA ◽  
Maria Luisa SIRICO ◽  
Pasquale GUASTAFERRO ◽  
Luigi Francesco MORRONE ◽  
Filippo NIGRO ◽  
...  

2012 ◽  
Vol 35 (5) ◽  
pp. 518-522 ◽  
Author(s):  
Lucia Di Micco ◽  
Serena Torraca ◽  
Maria Luisa Sirico ◽  
Domenico Tartaglia ◽  
Biagio Di Iorio

2016 ◽  
Vol 13 (4) ◽  
pp. 303-306 ◽  
Author(s):  
Xiao Zhang ◽  
Jian Jun Liu ◽  
Chee Fang Sum ◽  
Yeoh Lee Ying ◽  
Subramaniam Tavintharan ◽  
...  

Objective: To examine the relationship between inflammation and central arterial stiffness in a type 2 diabetes Asian cohort. Method: Central arterial stiffness was estimated by carotid-femoral pulse wave velocity and augmentation index. Linear regression model was used to evaluate the association of high-sensitivity C-reactive protein and soluble receptor for advanced glycation end products with pulse wave velocity and augmentation index. High-sensitivity C-reactive protein was analysed as a continuous variable and categories (<1, 1–3, and >3 mg/L). Results: There is no association between high-sensitivity C-reactive protein and pulse wave velocity. Augmentation index increased with high-sensitivity C-reactive protein as a continuous variable ( β = 0.328, p = 0.049) and categories ( β = 1.474, p = 0.008 for high-sensitivity C-reactive protein: 1–3 mg/L and β = 1.323, p = 0.019 for high-sensitivity C-reactive protein: >3 mg/L) after multivariable adjustment. No association was observed between augmentation index and soluble receptor for advanced glycation end products. Each unit increase in natural log–transformed soluble receptor for advanced glycation end products was associated with 0.328 m/s decrease in pulse wave velocity after multivariable adjustment ( p = 0.007). Conclusion: Elevated high-sensitivity C-reactive protein and decreased soluble receptor for advanced glycation end products are associated with augmentation index and pulse wave velocity, respectively, suggesting the potential role of systemic inflammation in the pathogenesis of central arterial stiffness in type 2 diabetes.


Author(s):  
S. V. Nedogoda ◽  
E. V. Chumachek ◽  
V. V. Tsoma ◽  
A. S. Salasyuk ◽  
V. O. Smirnova ◽  
...  

Aim. To assess the possibility of azilsartan medoxomil to achieve target blood pressure (BP) (less than 130/80 mm Hg), to study angioprotective features and reduction of adipokines levels and inflammatory markers in patients with hypertension and previous therapy with other ARBs.Material and methods. In open observational study with 24 weeks follow-up were included 60 patients with previous therapy (losartan or valsartan or telmisartan).All patients underwent ambulatory BP monitoring, applanation tonometry (determination of the augmentation index and central BP), measurement of the pulse wave velocity, laboratory tests (lipid profile, uric acid, fasting glucose, Homeostasis Model Assessment, homocysteine, leptin, adiponectin, highly sensitive C-reactive protein, tumor necrosis factor alpha, interleukin-6).Results. Azilsartan provided the systolic BP (29,05%, 22,5% and 8,9%) and diastolic BP reduction 18,82%, 20,46% and 8,54% (p<0,05) in patients previously treated with losartan, valsartan or telmisartan, respectively. Central systolic BP (by 25,95%, 8,78%, 11,94%), central pulse BP (by 40%, 18,38% and 19,6%), augmentation index (by 28,87%, 20,69% and 14,29%) and pulse wave velocity (by 21,57%, 24,56% and 24,92%) were decreased (p<0,05). There were positive changes in leptin, C-reactive protein, IL-6, adiponectin levels in all patients with losartan, valsartan or telmisartan initial therapy (p<0,05).Conclusion. Azilsartan medoxomil has advantages in BP control, the arterial elasticity improving, reducing of insulin-resistance and inflammation.


Sign in / Sign up

Export Citation Format

Share Document